Giant somatotrophinoma without acromegalic features: More "quiet" than "silent": Case report

Research output: Contribution to journalArticle

Abstract

OBJECTIVE AND IMPORTANCE: "Silent" somatotrophinomas are very rare, typically large pituitary adenomas that present with mild or no acromegalic features despite positive immunostaining for growth hormone and autonomous (nonglucosesuppressible) growth hormone secretion. Because of this, they may be amenable to treatment with somatostatin analogues. CLINICAL PRESENTATION: We report a giant somatotrophinoma (7 cm in maximal diameter) in a young woman with 6 years of amenorrhea who had no clinical features of acromegaly despite frankly elevated serum insulin-like growth factor 1 level at the time of diagnosis. Immunohistochemistry revealed focal strong positive staining for growth hormone in only 10% of the surgical specimen. Mutations in exons 8 or 9 of GNAS1, which are present in 40% of somatotrophinomas, were absent in the surgical specimen. The patient's clinical, biochemical, and radiological presentation is described and is compared with previously reported cases of silent somatotrophinomas. INTERVENTION: Because of the size and visual symptomatology, partial resection was performed via a transcranial approach. External adjuvant beam radiotherapy was used. As insulin-like growth factor 1 levels remained elevated, treatment with somatostatin analogue is being pursued. CONCLUSION: This case represents one of the largest somatotrophinomas described to date, and it demonstrates that serum insulin-like growth factor 1 should be measured even in the absence of acromegalic features in patients presenting with apparently nonsecreting macroadenomas. In addition to surgery and radiotherapy, somatostatin analogues may play an important role in controlling tumor growth.

Original languageEnglish (US)
JournalNeurosurgery
Volume56
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Somatomedins
Somatostatin
Growth Hormone
Adjuvant Radiotherapy
Acromegaly
Amenorrhea
Pituitary Neoplasms
Serum
Exons
Radiotherapy
Immunohistochemistry
Staining and Labeling
Mutation
Therapeutics
Growth
Neoplasms

Keywords

  • Growth hormone
  • Insulin-like growth factor 1
  • Somatotrophinoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

@article{c1a094b68772458a9fa7f59b7451b372,
title = "Giant somatotrophinoma without acromegalic features: More {"}quiet{"} than {"}silent{"}: Case report",
abstract = "OBJECTIVE AND IMPORTANCE: {"}Silent{"} somatotrophinomas are very rare, typically large pituitary adenomas that present with mild or no acromegalic features despite positive immunostaining for growth hormone and autonomous (nonglucosesuppressible) growth hormone secretion. Because of this, they may be amenable to treatment with somatostatin analogues. CLINICAL PRESENTATION: We report a giant somatotrophinoma (7 cm in maximal diameter) in a young woman with 6 years of amenorrhea who had no clinical features of acromegaly despite frankly elevated serum insulin-like growth factor 1 level at the time of diagnosis. Immunohistochemistry revealed focal strong positive staining for growth hormone in only 10{\%} of the surgical specimen. Mutations in exons 8 or 9 of GNAS1, which are present in 40{\%} of somatotrophinomas, were absent in the surgical specimen. The patient's clinical, biochemical, and radiological presentation is described and is compared with previously reported cases of silent somatotrophinomas. INTERVENTION: Because of the size and visual symptomatology, partial resection was performed via a transcranial approach. External adjuvant beam radiotherapy was used. As insulin-like growth factor 1 levels remained elevated, treatment with somatostatin analogue is being pursued. CONCLUSION: This case represents one of the largest somatotrophinomas described to date, and it demonstrates that serum insulin-like growth factor 1 should be measured even in the absence of acromegalic features in patients presenting with apparently nonsecreting macroadenomas. In addition to surgery and radiotherapy, somatostatin analogues may play an important role in controlling tumor growth.",
keywords = "Growth hormone, Insulin-like growth factor 1, Somatotrophinoma",
author = "Aniket Sidhaye and Peter Burger and Daniele Rigamonti and Roberto Salvatori",
year = "2005",
month = "5",
doi = "10.1227/01.NEU.0000157961.67867.E5",
language = "English (US)",
volume = "56",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Giant somatotrophinoma without acromegalic features

T2 - More "quiet" than "silent": Case report

AU - Sidhaye, Aniket

AU - Burger, Peter

AU - Rigamonti, Daniele

AU - Salvatori, Roberto

PY - 2005/5

Y1 - 2005/5

N2 - OBJECTIVE AND IMPORTANCE: "Silent" somatotrophinomas are very rare, typically large pituitary adenomas that present with mild or no acromegalic features despite positive immunostaining for growth hormone and autonomous (nonglucosesuppressible) growth hormone secretion. Because of this, they may be amenable to treatment with somatostatin analogues. CLINICAL PRESENTATION: We report a giant somatotrophinoma (7 cm in maximal diameter) in a young woman with 6 years of amenorrhea who had no clinical features of acromegaly despite frankly elevated serum insulin-like growth factor 1 level at the time of diagnosis. Immunohistochemistry revealed focal strong positive staining for growth hormone in only 10% of the surgical specimen. Mutations in exons 8 or 9 of GNAS1, which are present in 40% of somatotrophinomas, were absent in the surgical specimen. The patient's clinical, biochemical, and radiological presentation is described and is compared with previously reported cases of silent somatotrophinomas. INTERVENTION: Because of the size and visual symptomatology, partial resection was performed via a transcranial approach. External adjuvant beam radiotherapy was used. As insulin-like growth factor 1 levels remained elevated, treatment with somatostatin analogue is being pursued. CONCLUSION: This case represents one of the largest somatotrophinomas described to date, and it demonstrates that serum insulin-like growth factor 1 should be measured even in the absence of acromegalic features in patients presenting with apparently nonsecreting macroadenomas. In addition to surgery and radiotherapy, somatostatin analogues may play an important role in controlling tumor growth.

AB - OBJECTIVE AND IMPORTANCE: "Silent" somatotrophinomas are very rare, typically large pituitary adenomas that present with mild or no acromegalic features despite positive immunostaining for growth hormone and autonomous (nonglucosesuppressible) growth hormone secretion. Because of this, they may be amenable to treatment with somatostatin analogues. CLINICAL PRESENTATION: We report a giant somatotrophinoma (7 cm in maximal diameter) in a young woman with 6 years of amenorrhea who had no clinical features of acromegaly despite frankly elevated serum insulin-like growth factor 1 level at the time of diagnosis. Immunohistochemistry revealed focal strong positive staining for growth hormone in only 10% of the surgical specimen. Mutations in exons 8 or 9 of GNAS1, which are present in 40% of somatotrophinomas, were absent in the surgical specimen. The patient's clinical, biochemical, and radiological presentation is described and is compared with previously reported cases of silent somatotrophinomas. INTERVENTION: Because of the size and visual symptomatology, partial resection was performed via a transcranial approach. External adjuvant beam radiotherapy was used. As insulin-like growth factor 1 levels remained elevated, treatment with somatostatin analogue is being pursued. CONCLUSION: This case represents one of the largest somatotrophinomas described to date, and it demonstrates that serum insulin-like growth factor 1 should be measured even in the absence of acromegalic features in patients presenting with apparently nonsecreting macroadenomas. In addition to surgery and radiotherapy, somatostatin analogues may play an important role in controlling tumor growth.

KW - Growth hormone

KW - Insulin-like growth factor 1

KW - Somatotrophinoma

UR - http://www.scopus.com/inward/record.url?scp=18244365114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244365114&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000157961.67867.E5

DO - 10.1227/01.NEU.0000157961.67867.E5

M3 - Article

C2 - 15854264

AN - SCOPUS:18244365114

VL - 56

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -